Skip to content
Review Open access

Vaginal Microbiome-Based Strategy: From HPV Infection to Cervical Cancer

Oct 2026 · Clinical Medical Reviews and Case Reports · 0 citations

Abstract

Persistent high-risk human papillomavirus (HR-HPV) infection serves as the core prerequisite for cervical intraepithelial neoplasia (CIN) and invasive cervical cancer. Accumulated translational evidence confirms that vaginal microecological homeostasis dominated by protective Lactobacillus strains fundamentally governs the initiation, persistence, and spontaneous clearance of HR-HPV infection, while microbial dysbiosis featuring depleted lactobacilli and overgrown anaerobic pathogens creates a pro-inflammatory, immune-suppressive mucosal niche that accelerates viral retention and cervical malignant transformation. This review systematically delineates the bidirectional regulatory crosstalk between vaginal microbiota and HR-HPV: dysbiosis disrupts vaginal acidic barriers, reshapes local cytokine networks, impairs antiviral innate immunity, and modulates HPV E6/E7 oncogenic transcription; reciprocally, HR-HPV oncoproteins remodel microbial community structures to sustain a dysbiotic feedback loop. Age-dependent hormonal shifts, immune senescence, and controllable lifestyle factors reshape the virus-host-microbe tripartite axis, thereby significantly stratifying individual susceptibility. Three core carcinogenic cascades induced by dysbiotic flora are elaborated: epithelial barrier erosion, metabolic reprogramming, and epigenetic rewiring of host and viral genomes. A set of dynamic microbial characteristics is sorted out, corresponding to all stages of progressive cervical lesions, ranging from transient HPV infection to high-grade CIN and carcinoma. In addition, the bench-to-bedside translational progress of microbiome-targeted interventions from laboratory to clinical implementation is summarized. Interventions include single/multi-strain probiotic supplementation, engineered lactic acid bacterial therapeutic vaccine, vaginal microbiota transplantation, and traditional Chinese medicine therapy that can reconstruct vaginal eubiosis. The clinical application of microbial diversity, strain-level single-nucleotide variants, and taxonomic biomarkers is illustrated, which can be used for early screening of cervical cancer, predicting efficacy, and dividing the risk of postoperative recurrence. Finally, common bottlenecks in current transformation research are summarized: inconsistent standards for probiotic use, shortcomings in existing preclinical infection models, and inconclusive interaction mechanisms of gut-vagina microbiome. Meanwhile, the newly revealed application potential of artificial intelligence in multi-omics microbial data mining is introduced. This comprehensive research framework with vaginal microbiome as the core not only clarifies the internal mechanism of HR-HPV gradually developing into the whole pathway of cervical cancer, but also provides practical clinical means to block the progression cascade of HR-HPV-cervical cancer.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.